| Literature DB >> 34670754 |
S Iuliano1, S Poon1, J Robbins1, M Bui2, X Wang1, L De Groot3, M Van Loan4, A Ghasem Zadeh1, T Nguyen5,6, E Seeman1.
Abstract
OBJECTIVE: To assess the antifracture efficacy and safety of a nutritional intervention in institutionalised older adults replete in vitamin D but with mean intakes of 600 mg/day calcium and <1 g/kg body weight protein/day.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34670754 PMCID: PMC8527562 DOI: 10.1136/bmj.n2364
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Fig 1Flowchart for participating aged care facilities. Of 108 eligible facilities, 48 were excluded, leaving 60 randomised to intervention or control. Three intervention facilities and one control facility did not start study, leaving 27 intervention and 29 control facilities participating, of which two intervention facilities closed during study period. Median number of residents in intervention and control groups were 111 (interquartile range 75-147) and 125 (88-163), respectively; P=0.42 by Wilcoxon’s rank test
Baseline characteristics of residents in clusters assigned to two years of dairy supplementation (intervention) or maintenance of existing menu (controls). Values are mean (standard deviation) unless stated otherwise
| Characteristics | Intervention (n=3301) | Controls (n=3894) |
|---|---|---|
| No of clusters (facilities) | 27 | 29 |
| Median No of residents per cluster | 111 | 125 |
| No (%) female | 2311 (70) | 2609 (67) |
| Age, years | 86 (2.3) | 86 (2.2) |
| Height (m) | 1.60 (0.02) | 1.61 (0.03) |
| Weight (kg) | 66 (6.3) | 68 (8.4) |
| Median (IQR) medications | 11 (8-14) | 12 (9-16) |
| Median (IQR) medical conditions | 9 (7-12) | 10 (7-14) |
| No (%) with previous fracture | 184 (41) | 183 (37) |
| No (%) with cognitive impairment | 189 (52) | 237 (53) |
| No (%) with cardiovascular disease | 301 (66) | 309 (63) |
| No (%) malnourished, at risk, normal | 70 (17), 272 (66), 70 (17) | 25 (11), 158 (66), 55 (23) |
|
|
|
|
| 25-hydroxy-vitamin D, nmol/L | 72 (15) | 72 (21) |
| C terminal telopeptide of type 1 collagen, ng/mL | 0.41 (0.14) | 0.39 (0.11) |
| Procollagen type 1 N propeptide, μg/L | 52.9 (19.1) | 48.5 (9.7) |
| Parathyroid hormone, pg/mL | 6.85 (2.04) | 7.27 (1.74) |
| Insulin-like growth factor 1, nmol/L | 15.4 (2.8) | 15.1 (3.1) |
|
|
|
|
| Total lean mass, kg | 39.7 (8.6) | 39.8 (8.1) |
| Appendicular lean mass, kg | 16.3 (1.2) | 16.4 (3.7) |
| Fat mass, kg | 22.5 (9.5) | 27.2 (11.0) |
|
|
|
|
| Femoral neck BMD, g/cm2 | 0.76 (0.08) | 0.74 (0.12) |
| Lumbar spine BMD, g/cm2 | 1.08 (0.22) | 1.13 (0.23) |
| Distal tibia: | ||
| Total volumetric BMD, mgHA/cm3 | 215 (44) | 228 (63) |
| Cortical porosity, % | 75 (5.6) | 75 (6.6) |
| Trabecular volumetric BMD, mgHA/cm3 | 155 (35) | 167 (47) |
| Distal radius: | ||
| Total volumetric BMD, mgHA/cm3 | 257 (41) | 247 (68) |
| Cortical porosity, % | 68 (3.8) | 69 (7.5) |
| Trabecular volumetric BMD, mgHA/cm3 | 155 (34) | 148 (47) |
BMD=bone mineral density; IQR=interquartile range.
n=457 intervention; n=494 controls.
Mini Nutrition Assessment Score: 24-30=normal nutritional status; 17- 23.5=at risk of malnutrition; <17=malnourished (n=412 intervention; n=238 controls).
Fig 2Mean (SD) daily dietary intake of dairy servings, energy, calcium, and protein at baseline (regular menu) and during two year study period in intervention group compared with controls. *P<0.05 denotes significant difference between groups at corresponding time point
Mean (standard deviation) percentage change from baseline at month 12 in biochemistry and bone morphology in each group and between group mean percentage difference with 95% confidence interval.
| Intervention | Control | Mean between group difference (95% CI) | P value | |
|---|---|---|---|---|
|
| (n=106) | (n=83) | ||
| Bone resorption marker (CTX) | −7.3 (40.7) | 13.1 (45.5) | −20.4 (−33.2 to −7.6) | 0.002 |
| Bone formation marker (P1NP) | −4.7 (35.4) | −3.9 (55.1) | −0.8 (−14.6 to 12.9) | 0.90 |
| Parathyroid hormone | 1.1 (20.7) | −0.16 (32.0) | 1.3 (−6.7 to 9.2) | 0.76 |
| Insulin-like growth factor-1 | 5.9 (27.0) | −2.0 (22.4) | 7.9 (15.7 to 0.2) | 0.04 |
|
| (n=33) | (n=39) | ||
| Lumbar spine BMD | 2.1 (2.7) | 0.3 (2.4) | 1.8 (0.1 to 3.5) | 0.04 |
| Femoral neck BMD | 0.7 (3.0) | −1.0 (4.4) | 1.7 (−0.3 to 3.7) | 0.09 |
| Distal radius: | ||||
| Total volumetric BMD | 0.7 (2.7) | −2.6 (5.6) | 3.3 (0.6 to 6.0) | 0.02 |
| Trabecular volumetric BMD | 0.9 (2.3) | −3.5 (8.7) | 4.6 (0.4 to 8.2) | 0.03 |
| Cortical porosity | 0.0 (1.7) | 0.7 (3.3) | −0.6 (−2.3 to 1.0) | 0.43 |
| Distal tibia: | ||||
| Total volumetric BMD | −0.1 (2.5) | −2.1 (4.4) | 2.0 (−0.1 to 4.2) | 0.07 |
| Trabecular volumetric BMD | 0.2 (2.3) | −2.2 (8.5) | 2.4 (−1.4 to 6.2) | 0.21 |
| Cortical porosity | 0.4 (1.3) | 0.7 (1.2) | −0.3 (−1.1 to 0.4) | 0.39 |
|
| (n=33) | (n=39) | ||
| Body weight | 0.6 (8.3) | −1.9 (5.2) | 2.5 (0.6 to 4.1) | 0.009 |
| Lean mass | −0.2 (2.7) | −0.4 (2.8) | 0.3 (−0.9 to 1.6) | 0.60 |
| Appendicular lean mass | 0.3 (4.5) | −1.7 (5.0) | 2.0 (0.02 to 4.1) | 0.05 |
| Fat mass | 3.8 (20.6) | −3.3 (8.1) | 7.3 (0.1 to 14.5) | 0.05 |
BMD=bone mineral density; CTX=C terminal telopeptide of type 1 collagen; P1NP=procollagen type 1 N propeptide.
P<0.05 for difference from baseline within group.
P<0.001 for difference from baseline within group.
Fig 3Cumulative probability of event over 24 months for all fractures, hip fractures, falls, and mortality in intervention group and controls. Numbers of participants in two groups at risk for each event are shown below panels